Anshidalai Pharmacy (China) Co., Ltd. Anshidalai Pharmacy (China) Co., Ltd.

Anshitai Pharmaceutical (China) Co., Ltd. (hereinafter referred to as Anshitai China) was renamed from Yamanouchi Pharmaceutical (China) Co., Ltd. in August 2005 and merged with Fujisawa Pharmaceutical (China) Co., Ltd. on April 1 2007. The original two companies have a factory history of over 12 years in China, and have established a good reputation. The merger has realized the complementarity of the main product lines, expanded the product business scope, and concentrated Chinese resources to carry out research and development of a variety of high-quality drugs. Anstler China takes the continuous meeting of customers' needs as its top priority, upholds high ethics and conducts business activities in line with laws and regulations. Give full play to creativity under the mission of enhancing enterprise value. Achieve sustainable business development and strive to become an enterprise trusted by China customers, employees, government, related enterprises, social groups and other stakeholders.

(Beijing, April 65438+March 2007) Anstalai Pharmaceutical (China) Co., Ltd. today officially announced the merger of Fujisawa Pharmaceutical (China) Co., Ltd. and Anstalai Pharmaceutical (China) Co., Ltd., which marked the final global merger of Anstalai Pharmaceutical Group in China.

In fiscal year 2005 (fiscal year ending in March 2006), Anshitai's global net sales were 880 billion yen (about 57.8 billion RMB), making it the second largest prescription drug company in Japan and the largest pharmaceutical group in the world. Before the merger, the original two companies had a factory history of more than 12 years in China, and had a good reputation. The merged company will quickly establish a business system in the field of targeted therapy, strengthen its global competitiveness in the future, and become a leading pharmaceutical company in the field of global disease treatment.

The merger makes the main product lines of the two companies complement each other, which can expand the product business scope and focus on the research and development of various excellent drugs. Mr. Yoko Hideyoshi, General Manager of Anstler China, introduced that the main business projects of Anstler China are the production, sales and development of drugs. The main products include prozac, an immunosuppressant used to prevent and treat organ transplantation. reg； Harry &; Reg and gosta are used to treat peptic ulcer & reg； Putebi, a drug for the treatment of atopic dermatitis; reg； Micamin & reg；, an anti-fungal drug for deep infection; Pell &; Reg and the treatment of nausea and vomiting caused by anti-malignant tumor treatment. Reg and so on, *** 1 1 different varieties. It is planned to achieve sales of about 600 million yuan in fiscal year 2007.

After the merger, China Anshilai has about 490 employees, distributed in Shenyang production plant and branches and liaison offices in major cities in China. In addition to continuously optimizing the advanced production technology of Shenyang Pharmaceutical Factory, improving the domestic sales network and improving the professional quality of personnel, Astra China will also expand cooperation with China research institutions through cooperative development system. Astaire China is one of the largest Japanese pharmaceutical companies in China and a wholly-owned subsidiary of Astaire Pharmaceutical Group in China. The factory is located in Shenyang Economic Development Zone, headquartered in Beijing, with branches in Shanghai, Beijing, Guangzhou, Chengdu and Shenyang, covering large and medium-sized cities across the country, with about 500 employees nationwide.

At present, the products sold by Anstler China in China involve organ transplantation, urology, infection, skin, digestive circulation and other professional fields, among which the products in the fields of transplantation and urology have been recognized by doctors and patients and are in a leading position in the market. In April 2005, the business of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Industry Co., Ltd. was integrated, and Anshilai Pharmaceutical Group was established.

Anshilai Pharmaceutical Group is a research and development pharmaceutical enterprise headquartered in Tokyo, Japan. It is the second largest prescription drug company in Japan and the 18 largest pharmaceutical group in the world. R&D produces and sells innovative pharmaceutical products on a global scale. We are committed to making contributions to the health of people all over the world through innovative and reliable pharmaceutical products, realizing our significance of existence, and our mission is to continuously enhance the value of enterprises.

Combined with the external market environment, the company's existing advantages and future development potential, facing the competition in the global market, we have determined a competitive business model-that is, to become a "global professional therapy leader" in six key treatment fields. Japanese pharmaceutical companies, which have always been low-key, began to make frequent appearances, exerting their strength in the pharmaceutical market in China. Recently, Zhuo Yongqing, general manager of China Company, the largest Japanese pharmaceutical company, said in Beijing that with the continuous expansion of medical insurance coverage, the pharmaceutical market in China will develop greatly in the future, and Astaire will continue to increase its investment in China and never give up any opportunity, and at least five new drug varieties will be introduced to the China market in the next five years. On April 1 this year, Zhuo Yongqing became the general manager of Anshilai (China) Co., Ltd. and concurrently served as the vice chairman of China Foreign-invested Pharmaceutical Association. A few days ago, Anstalay Pharmaceutical China Company held a press conference in Beijing. When talking about whether to consider the acquisition of Chinese enterprises, Zhuo Yongqing said that the acquisition of Chinese enterprises will be a very long process and requires careful market research. Astaire "will never give up any opportunity", but it will be very cautious in the process of pursuing the acquisition.

Last year, its sales in China was about 750 million yuan.

As early as 2005, two pharmaceutical companies, Yamanouchi and Fujisawa, merged to form Anshilai Pharmaceutical, each holding 50% of the shares. According to Zhuo Yongqing, in 2008, the sales of Anstler in China was about 750 million yuan. Zhuo Yongqing said that after the merger of the two pharmaceutical companies, Anshitai Pharmaceutical grew by more than 20% every year, and the sales share of the entire Asian subsidiary accounted for 3% of the world, accounting for about 45%-47% of Asia in the first half of this year, which is equivalent to Anshitai's business in China accounting for more than 1% of the global business.

Compared with European and American pharmaceutical giants, Japanese pharmaceutical companies including Anshitai started relatively late, and their share in the global pharmaceutical field is limited. In response to a question from Tencent Finance, Zhuo Yongqing said that in the late 1980s, Japanese pharmaceutical companies did have some products in the US market, which determined the current status of Japanese pharmaceutical companies in the world. Zhuo Yongqing believes that Anshitai has achieved global leadership in organ transplant drugs and cephalosporins. Japanese pharmaceutical companies must seek breakthroughs in new drug research and development and global marketing network in order to occupy a place in the global pharmaceutical industry.

The new medical reform brings huge business opportunities.

Talking about the impact of the financial crisis on the business of Anstalai, Zhuo Yongqing believes that the impact of the crisis on the growth of Anstalai is very small, because all the subsidiaries of Anstalai have grown very well in local currency. "Specifically, it can be said that it has no impact, but it has an impact on financial statements." Zhuo Yongqing said that since Anshilai is a company listed in Japan, the currency of financial statements is Japanese yen. "The depreciation of the US dollar is partly good-looking, and the world is not good-looking." Zhuo Yongqing believes that the financial crisis has little impact on the business of Anstler in China. On the contrary, the medical reform and creation in the past two years have brought market opportunities. "In the past six months, I have talked with many deans and many doctors. They said that there are more and more inpatients, which shows that the pharmaceutical market in China is still growing. " Zhuo Yongqing said that last year, the sales volume of some varieties of Anstalai increased by 20%-30%, and the growth rate of a few varieties exceeded 60%. Of course, some varieties are not ideal, and health care drugs may have the greatest impact.

Japanese enterprises cultivate generalists.

Since 1976 joined Fujisawa Pharmaceutical Taiwan Province Office, Zhuo Yongqing has served Fujisawa Pharmaceutical (including the merged Anstalai) for 33 years. "I also feel like a freak. I started as a medical representative. At first, I was in charge of the clinic market in Taiwan Province Province, and later I went to run a big hospital like Chang Gung Memorial Hospital. " Zhuo Yongqing said that he has worked as a drug registration, medical representative and planning manager. Later, I also did OTC sales and TV advertisements, almost all of which I did, and also represented other multinational pharmaceutical companies in Taiwan Province Province.

Zhuo Yongqing said that in the employment mechanism, there is a basic difference between European and American pharmaceutical companies and Japanese pharmaceutical companies, that is, Japanese companies cultivate generalists, while European and American pharmaceutical companies cultivate majors. "European and American companies need you to have a professional job description in order to take the corresponding position and stay in that position." Zhuo Yongqing said that Japanese companies will not say that there is only one function, such as the lack of personnel in the personnel department. "You are a sales manager, it is possible to pull you to the personnel department. Japanese companies should cultivate a generalist who can make you jump around. " Compared with European and American companies, each has its own advantages and disadvantages. Existential significance

By providing innovative and reliable medical products and contributing to the health of people all over the world, we will continue to explore and discover the potential of life sciences, meet challenges, and develop innovative drugs with efforts beyond others; By providing reliable and high-quality products and scientific and rigorous medical information, win the high trust of customers; Help people all over the world live a healthy life and become a dazzling star in the global pharmaceutical industry.

delegation

Continuously enhance the value of the enterprise.

Anstar pursues the continuous improvement of enterprise value.

Astaire strives to become an enterprise chosen and trusted by stakeholders, thus enhancing its own corporate value. Our stakeholders include customers, shareholders, employees and global social groups.

principle

Credo provides a daily code of conduct that we are proud of, and Estelle always takes Credo as our guide.

High morality always adheres to high moral integrity and conducts business activities.

Customer first, always grasp customer needs, and take meeting customer needs as the action guide.

Give full play to creativity, be dissatisfied with the status quo, aim high, challenge self-innovation and create new value.

The view of competition broadens the horizon, looks at the outside world and creates new value before competitors. In 2008, Anshitai Pharmaceutical Group ranked 35th among Newsweek's top 500 companies in the world, first among all Japanese companies, and eighth among global pharmaceutical companies. On July 9, 2008, the Japanese edition of Newsweek published the list of the world's top 500. In 2008, Newsweek ranked among the top 500 companies in the world. Among the top 65,438+0,000 companies with sales in 2006, through comprehensive evaluation based on financial performance and corporate social responsibility (CSR), 500 outstanding companies in the world were selected. The financial performance score of an enterprise combines profitability, growth and security: profitability reflects the operating profit rate of assets (operating profit/total assets) and sales (operating profit/sales) of an enterprise; Growth combines the average annual growth rate of sales with the annual cash flow statement of the enterprise; Security focuses on assessing the ratio of the enterprise's ability to pay interest [(pre-tax profit+interest payment)/interest payment]. The total score of financial performance of Anstalai Pharmaceutical Group is 56, ranking first among pharmaceutical enterprises, among which the score of growth and safety is 20.

Corporate social responsibility (CSR) is evaluated from four aspects: enterprise management, employee development, social contribution and environmental protection. Relevant data comes from Eiris (Ethical Investment Research Service), a British professional survey company.

Anshilai Pharmaceutical Group is a young enterprise, which was established by the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical on April 1 2005. It has been devoted to research and development of innovative and reliable pharmaceutical products, contributing to the health of people all over the world, and realizing our mission by constantly improving the value of enterprises. In corporate vision 20 15, the future development direction of anstalai is defined, that is, in the highly specialized treatment field where there is no effective treatment method at present, we should concentrate our advantages and resources on product research and development, and highlight higher competitiveness by providing high value-added products on a global scale, so as to become a global leader in the field of professional treatment. The six key areas are organ transplantation immunosuppression/inflammation, urology, infectious diseases, central nervous system/pain, diabetes and tumors.

At present, the CSR-based management system implemented by AXA Pharmaceutical Group means that we should not only be accepted by customers in global market activities, but also be recognized and respected in many aspects such as management, social interaction and humanistic care, and become an important member in social activities. 1994 10 A pharmaceutical company was established in Shenyang.

1March, 1997, Shenyang development zone factory was put into production.

199765438+obtained GMP certification in China in February.

1998165438+10 was certified by ISO-9002 environmental quality system in October.

In June, 20001year, Shenyang Shannei Pharmaceutical Company was changed into a wholly-owned enterprise.

200 1 10 was certified by ISO- 1400 1 environmental quality system.

In May 2002, it was officially renamed as Yamanouchi Pharmaceutical (China) Co., Ltd.

In February 2003, we obtained the high-tech enterprise certification and ISO-900 1-2000 version certification.

In August 2005, the name of the company was changed to Anstalai Pharmaceutical (China) Co., Ltd.

In March 2006, ISO- 14000 and ISO-9000 were integrated.

In April, 2007, it merged with Fujisawa Pharmaceutical (China) Co., Ltd. to produce Anshitai pharmaceutical products: Propranolol for transplant infection; (Tacrolimus) Micael; (Micafenone sodium) urocutaneous Viciakang; (Solina Sin) Harry; Putby (tamsulosin hydrochloride); (tacrolimus) Dana of digestive cycle; (beraprost sodium) Kosuda; (famotidine) Pell; (nicardipine hydrochloride)